- Home
- CUB vs ACIU Comparison
CUB vs ACIU Comparison
Compare CUB & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUB
- ACIU
- Stock Information
- Founded
- CUB 2024
- ACIU 2003
- Country
- CUB United States
- ACIU Switzerland
- Employees
- CUB N/A
- ACIU N/A
- Industry
- CUB
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- CUB
- ACIU Health Care
- Exchange
- CUB NYSE
- ACIU Nasdaq
- Market Cap
- CUB 307.3M
- ACIU 332.4M
- IPO Year
- CUB 2024
- ACIU 2016
- Fundamental
- Price
- CUB $10.09
- ACIU $2.71
- Analyst Decision
- CUB
- ACIU Strong Buy
- Analyst Count
- CUB 0
- ACIU 2
- Target Price
- CUB N/A
- ACIU $12.00
- AVG Volume (30 Days)
- CUB 61.4K
- ACIU 130.0K
- Earning Date
- CUB 01-01-0001
- ACIU 11-05-2024
- Dividend Yield
- CUB N/A
- ACIU N/A
- EPS Growth
- CUB N/A
- ACIU N/A
- EPS
- CUB N/A
- ACIU N/A
- Revenue
- CUB N/A
- ACIU $48,505,404.00
- Revenue This Year
- CUB N/A
- ACIU $85.33
- Revenue Next Year
- CUB N/A
- ACIU $80.69
- P/E Ratio
- CUB N/A
- ACIU N/A
- Revenue Growth
- CUB N/A
- ACIU 4097200.00
- 52 Week Low
- CUB $9.96
- ACIU $2.25
- 52 Week High
- CUB $10.55
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- CUB N/A
- ACIU 29.89
- Support Level
- CUB N/A
- ACIU $2.62
- Resistance Level
- CUB N/A
- ACIU $3.07
- Average True Range (ATR)
- CUB 0.00
- ACIU 0.15
- MACD
- CUB 0.00
- ACIU -0.04
- Stochastic Oscillator
- CUB 0.00
- ACIU 17.24
About CUB LIONHEART HOLDINGS
Lionheart Holdings is a blank check company.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.